BACKGROUND: Safety profiles of biologics for treatment of @entity1569 are limited to data from randomized controlled trials. There is a need for comparative safety reports of biologics based on data from clinical practice. OBJECTIVE: We sought to estimate and compare the incidence of adverse events (AEs) leading to withdrawal of biologics (etanercept, infliximab, adalimumab, and ustekinumab) in the treatment of @entity1569 . METHODS: We conducted a multicenter retrospective chart review from September 2005 to September 2014. Incidence proportion and rate of AEs leading to withdrawal by biologic agent and AE were calculated. RESULTS: For 545 treatments administered in 398 @entity1 , 22 (4.04%) AEs were associated with withdrawal, for a rate of 1.97/100 @entity1 -years (95% confidence interval [CI] 1.32-2.94). Common AEs were injection-/infusion-site reactions (0.55%, 0.92%, 0%, and 0% for etanercept, infliximab, adalimumab, and ustekinumab, respectively); @entity281 (0%, 0.18%, 0.55%, 0.18%); and @entity5 (0.18%, 0.18%, 0%, 0.37%). LIMITATIONS: Possible incompleteness of chart details and small study population limit the conclusiveness of findings. CONCLUSION: Biologic agents for treatment of @entity1569 are safe; AEs associated with withdrawal occurred in 4% of all administered biologic therapies. It does not appear that real-world @entity1 encounter more AEs with biologics than @entity1 in clinical trials.

Adverse events resulting in withdrawal of biologic therapy for XXXX in real-world clinical practice: A Canadian multicenter retrospective study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infections'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies'] @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis']
@entity1569 :: (MESH:D011565,Disease) :: ['psoriasis']
